

Time	DAY 1: 29 SEPTEMBER 2024			
07:00 - 12:00	Registrations and Poster Set Up			
	Great Hall 1 and 2			
08:00 - 10:20	Welcome to Country, Plenary Speakers and Schild Award			
08:00 - 08:25	Welcome to Country and Opening Remarks			
08:25 - 09:00	Opening Plenary Session Chairs: Kirsty Short and Maria Zambon Jeremy Farrar, World Health Organization, Switzerland Influenza - From the outside looking in			
09:00 - 09:35	Mark von Itzstein, Griffith University, Australia The glycointeractome of clinically-significant respiratory viruses and drug discovery			
09:35 - 09:45	Introducing Schild Lecture Maria Zambon and Mark Tompkins			
09:45 - 10:20	Schild Lecture Florian Krammer, Icahn School of Medicine at Mount Sinai, USA; Medical University of Vienna, Austria			
10:20 - 10:50	Morning Tea			
	Great Hall 1 and 2			
10:50 - 11:50	Panel Discussion H5N1 HPAI 1996 - 2024: What has changed and how worried should we be today? Chair: Kanta Subbarao Jeremy Farrar, Amelia Coggon, Yoshi Kawaoka, Erik Karlsson, Florian Krammer, Amy Baker			
11:50 - 12:50	Great Hall 1 and 2	Mezzanine Room M3	Mezzanine Room M4	Mezzanine Room M1 and M2
	Challenges in the clinical development of vaccines with enhanced neuraminidase immunogenicity Sponsored by Moderna Chair: Florian Krammer	Late Breaking Abstracts Chairs: Ultan Power and Fred Hayden	Late Breaking Abstracts Chairs: Melanie Wu and Shashank Tripathi	Influenza and Diabetes (ESWI) Chair: Kirsty Short
11:50 - 12:03		Hannah Stacey: Evidence of local B-cell immunity following live-attenuated influenza vaccination of humans	Colin Russell: Later seasonal influenza virus vaccine strain selection can improve match of vaccine viruses to circulating viruses	Panel Discussion: Oana Sandulescu, Katina Hulme, Tor Biering-Sorensen
12:03 - 12:16		Martha Alexander-Miller: Antibody Function Predicts Viral Control in Newborn African Green Monkeys Immunized with an Influenza Virus HA Stem Nanoparticle	Oliver Eales: Biases in routine influenza surveillance indicators used to monitor infection incidence and recommendations for improvement	
12:16 - 12:29		Tereza Masonou: SARS-CoV-2 infection of nasal epithelial cells from children results in greater neutrophil trans-epithelial migration, but a more activated neutrophil phenotype emerges in older adults	Benoit Callendret: Phase 3 Safety and Immunogenicity of an mRNA-Based Seasonal Influenza and SARS-CoV-2 Multicomponent Vaccine (mRNA-1083) Compared With Co-administered Licensed Vaccines in Adults ≥50 Years Old	
12:29 - 12:42		Goran Bajic: Cryo-EM structure and protection mechanism of human antibody lineages that recognize quaternary epitopes on influenza hemagglutinin	Rose Miller: Spike-directed immunity to multiple coronaviruses in ferrets	
12:50 - 13:35	Lunch and Poster Viewing			
13:35 - 14:35	Industry Symposium: AstraZeneca From virus to vaccine: the journey to a seasonal influenza vaccine Chair: Peter Openshaw Ian Barr, Lauren Parker, Cheryl Cohen, Christopher Blyth (Great Hall 1 and 2)			
14:50 - 15:50	Industry Symposium: Pfizer Combatting Co-circulation of Respiratory Viruses: Meeting the Public Health Challenge Chair: Michael Moore AM Charles Feldman, Raina MacIntyre, Holly Seale			
15:50 - 16:20	Afternoon Tea			
16:20 - 18:30	Great Hall 1 and 2			
	First Nations populations: Respiratory Disease, Vaccination, and Implementation Chair: Bronwyn Fredericks			
16:30 - 17:00	Katherine Kedzierska, The University of Melbourne, Australia Defining immunity to respiratory viral infections in Australian First Nations peoples			
17:00 - 18:00	Panel Discussion Chair: Bronwyn Fredericks Jane Davies, Menzies School of Health Research, Australia Teresa de Santis, Northern Territory Health, Australia Adrian Miller, CQ University, Australia Matire Harwood, University of Auckland, New Zealand			
18:00 - 18:30	A discussion with Noble Laureate Peter Doherty Introduction by Katherine Kedzierska, The University of Melbourne, Australia			

18:30 - 20:30	Welcome Reception and Poster Session 1
20:30 - Late	ECR Networking Event (Sponsored by ISIRV)

Time	DAY 2: 30 SEPTEMBER 2024				
07:00 - 12:00	Registrations and Poster Set Up				
	Great Hall 1 and 2				
08:00 - 10:00	Transmission				
08:00 - 08:10	Opening - Conference Business and Session welcome Chairs: Rebecca Cox and Mark Tompkins				
08:10 - 08:45	Cheryl Cohen, University of the Witwatersrand, South Africa Impact of immunity on respiratory virus transmission in South Africa				
08:45 - 09:20	Seema Lakdawala, Emory University, USA Every breath you take: Transmission of Influenza Viruses				
09:20 - 09:55	Aubree Gordon, University of Michigan, USA Nicaraguan Field Studies to Examine Influenza Transmission and Immunity				
10:00 - 10:30	Morning Tea				
10:30 - 12:00	Mezzanine Room M3	Mezzanine Room M4	Mezzanine Room M1 and M2	Great Hall 1 and 2	
	Virology and Pathogenesis NIV IG Session: Avian influenza at the species interface Chairs: Diane Post and Michelle Wille	Clinical Sciences and Vaccinology Clinical trials Chairs: Ben Cowling and Robin Mason	Interdisciplinary Session Respiratory viruses in underserved populations Chairs: Cheryl Cohen and Jane Davies	10:30 - 12:00	Public Health and Policy Forecasting, seasonality and surveillance Chairs: Matt Biggerstaff and Pejman Rohani
10:30 - 10:55	Erik Karlsson	Ben Cowling: Phase III CENTERSTONE study of single-dose baloxavir marboxil for the reduction of transmission of influenza in households	Vasiti Uluiviti: Enhancing laboratory preparedness and response to pandemics and respiratory virus surveillance in the US-affiliated Pacific Islands	10:30-10:43	Matthew Biggerstaff: In-season evaluation of influenza forecasts during the 2023-2024 United States influenza season
10:55 - 11:08	Agustina Rimondi: Outbreaks of HPAI H5N1 (2.3.4.4b) on Argentina's Atlantic coast: increased evidence for mammal-to-mammal transmission of a novel H5N1 clade in marine mammals.	Jianyu Lai: Evaluating Modes of Influenza Transmission (EMIT-2): An Ongoing Controlled Human Influenza Virus Infection Transmission Trial (CHIVITT)	Anders Madsen: Reducing Influenza Infection and Antibiotic Use in Young Children after Quadrivalent Influenza Vaccination; Insights from Rural Bangladesh	10:43-10:56	Rachael Pung: Integrating passive and sentinel surveillance for robust evaluation of SARS-CoV-2 infections
11:08 - 11:21	Michelle Wille: Emergence and spread of high pathogenicity avian influenza (HPAI) H5 in wildlife of South America and Antarctica	Pamuk Bilsel: Co-administration of Intranasal M2SR (M2-deficient Single Replication) Influenza Vaccine with Fluzone High Dose Induces Superior Immune Responses to Fluzone High Dose in Older Adults	Jorim Ayugi: Illness outcomes of in-and-out patients co-infected with SARS-CoV-2 and Malaria, 2020-2022	10:56-11:09	Brendan Case: Charting the Course for Respiratory Virus Activity in the Southern Hemisphere: Real-Time Forecasting of Severe Acute Respiratory Infections in Paraguay, 2024
11:21 - 11:34	Samuel Ago: Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b Virus Detected in Poultry in Ghana, 2021 to 2022.	Alexandre Le Vert: OVX836, A NP-Based Universal Influenza Vaccine Candidate, Triggers Effector CD4+ and Cytotoxic CD8+ T Cells in Healthy Adults	Faletoese Asafo: The Social and Economic impacts of Early Childhood Hospitalisation with Respiratory Infection in Pacific families in Aotearoa, New Zealand.	11:09-11:22	Sheikh Taslim Ali: Time-varying inference of population immunity and prediction of influenza dynamics in Hong Kong
11:34 - 11:47	Carrie Reed: Human Infection with Highly Pathogenic Avian Influenza A(H5N1) Virus in a Dairy Worker in the United States	Amanda Rudman Spergel: Phase 1/2 Safety and Immunogenicity of mRNA-Based Seasonal Influenza and SARS-CoV-2 Multicomponent Vaccine in Healthy Adults	Felicity Ware: Kohanga winter preparedness project	11:22-11:35	David Muscatello: Improving emergency department surveillance to nowcast severe COVID-19 and influenza infection outcomes for epidemic intelligence
11:47 - 12:00	Ghazi Kayali: Sero-evidence of human infection with H5N1 and H9N2 avian influenza viruses	Pedro Folegatti: Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years	Jinal Bhiman: Antibody dynamics during prolonged SARS-CoV-2 infection in people living with and without HIV	11:35-11:48	Pejman Rohani: Forecasting influenza with ensembles of seasonal models
12:00 - 12:13				11:48-12:01	Warda Haque: Surveillance of Respiratory Virus Dynamics in 2021-2022: Insights from an Influenza Vaccine Clinical Trial in Bangladesh
12:00 - 13:00	Mezzanine Room M3	Lunch and Poster Viewing			
	ECR Career Development Lunch Susan Alisons Maria Auladell Kathy Spindler				
13:00 - 14:00	Industry Symposium: CSL Seqirus Strengthening Influenza Protection: A symposium on paediatric, pandemic and pioneering solutions Chair: Sarah Londrigan Terry Nolan AO, Colin Russell, Kanta Subbarao (Great Hall 1 and 2)				
14:00 - 15:30	Great Hall 1 and 2	Mezzanine Room M3	Mezzanine Room M4	Mezzanine Room M1 and M2	
	Public Health and Policy Vaccines 1: Real-world vaccine effectiveness Chairs: Annette Regan and Esther Kissling	Other Respiratory Viruses Respiratory virus surveillance and burden of disease Chairs: Yanshan Zhu and Viviana Simon	Interdisciplinary Session Viral evolution and public health genomics Chairs: Qiu Sue Huang and Juliana Leite	Virology and Pathogenesis Virus-host cell interactions Chairs: Anice Lowen and Kohei Oishi	
14:00 - 14:25	Annette Regan: Novel and Emerging Surveillance Systems for Monitoring the Real World Safety and Effectiveness of Vaccines in Pregnancy	Viviana Simon: Tracking trouble: Pathogen surveillance in a large metropolitan health care system	David Wentworth: Exploiting Viral Genomics to Develop and Improve Vaccines	Ana Fernández-Sesma: Modulation of innate immunity by influenza viruses	

14:25 - 14:38	Melissa Andrew: Influenza vaccine effectiveness in the prevention of admission to Assisted Living or Long-Term Care Facilities: A report from the Canadian Immunization Research Network SOS Network	Rhys Wenlock: High SARS-CoV-2 incidence and asymptomatic fraction during Delta and Omicron BA.1 waves in The Gambia	John Huddleston: Effects of delayed sequence submission and vaccine development on long-term forecast accuracy of seasonal influenza A/H3N2	Anice Lowen: Dispersing inwards: how within-host dispersal shapes influenza virus diversity	
14:38 - 14:51	Mary Patricia Nowalk: Exploring COVID-19 home testing and its impact on COVID-19 vaccine effectiveness estimates	Lea Separovic: Shift in the age distribution of pediatric and adult respiratory syncytial virus infections related to the COVID-19 pandemic: 2014/15 to 2023/24 seasons, British Columbia, Canada	Wenjie Han: Antigenic evolution patterns of influenza B viruses: insights into the disappearance of B/Yamagata	Antoni Wrobel: Molecular determinants of influenza haemagglutinin binding to a protein receptor	
14:51 - 15:04	Aleda Leis: Evaluation of test-negative design estimates of influenza vaccine effectiveness in the context of multiple, co-circulating, vaccine preventable respiratory viruses: a single-center analysis	Songwei Shan: Population-based disease burden associated with respiratory syncytial virus in Hong Kong, 1998-2019	Lu Lu: Unveiling the Complex Reassortment Patterns of Highly Pathogenic Avian Influenza H5 Virus	Chengjun Li: ABTB1 facilitates the replication of influenza A virus by counteracting TRIM4-mediated degradation of viral NP protein	
15:04 - 15:17	Susana Monge: Comparison of two methods for the estimation of COVID-19 vaccine effectiveness of the autumnal booster within the VEBIS-EHR network in 2022/23	Nikki Turner: Comparison of the burden and temporal pattern of hospitalizations associated with respiratory syncytial virus (RSV) before and after the COVID-19 pandemic in New Zealand	Yi Mo Deng: Expanded diversity of influenza viruses following the COVID-19 pandemic-induced bottleneck in Australia	Kohei Oishi: Archaeal kink-turn binding protein mediates inhibition of Orthomyxovirus splicing biology	
15:17 - 15:30	Bette Liu: Monitoring of COVID-19 vaccine effectiveness against COVID-19 mortality in Australia	Emily Martin: Evaluating the impact of viral coinfection on household transmission of respiratory viruses	Leo Poon: Genomic Surveillance Effectiveness on Global Dissemination of SARS-CoV-2 Omicron Variants	Kyle Macauley: Influenza A virus infection induces global desialylation of host glycoproteins	
15:30 - 16:00	Afternoon Tea				
16:00 - 17:00	Industry Symposium: Roche Stop the flu going viral: the benefits of antivirals for patients, households and communities Chair: Frederick G. Hayden Mei Zeng, Ben Cowling, Colin Russell (Great Hall 1 and 2)				
17:00 - 18:30	Great Hall 1 and 2		Mezzanine Room M3	Mezzanine Room M4	Mezzanine Room M1 and M2
	Public Health and Policy		Virology and Pathogenesis	Interdisciplinary Session	Other Respiratory Viruses
	Vaccines 2: from early development to the real world	17:00 - 18:30	Innate and mucosal immunity to infection	Imprinting, Aging and viral infection	RSV prevention and treatment
	<i>Chairs: Hannah Moore and Sheena Sullivan</i>		<i>Chairs: Stephanie Langel and Helena Aagaard Laybourn</i>	<i>Chairs: Robert Booy and Sook San Wong</i>	<i>Chairs: Kirsten Spann and Jeffrey Nielsen</i>
17:00 - 17:13	Cheng Chang: Pre-clinical comparison of sa-mRNA vs mRNA flu vaccines	17:00 - 17:25	Peter Openshaw: Acute and delayed effects of acute respiratory viral infections	Carolien Van de Sandt: Influenza virus-specific CD8+ T cells across the human lifespan: a paradoxical blend of stability and dynamic changes	Ann Falsey: RSV Vaccination in Older Adults: The Time Has Come
17:13 - 17:26	Kelly Lindert: Efficacy and Immunogenicity Results of Messenger RNA Influenza Vaccine in Adults 18-64	17:25 - 17:38	Brendon Y Chua: High expression of oleoyl-ACP-hydrolase underpins severe and life-threatening respiratory viral diseases	Marios Koutsakos: Conservation of major antigenic sites within each antigenic lineage underpins immunological imprinting to the influenza B virus haemagglutinin	Jeffery Neilsen: Novel Ligand-Targeted Immunotherapy for the treatment of Human Respiratory Syncytial Virus
17:26 - 17:39	Hyeeun Lee: Safety profile and breakthrough infections among quadrivalent influenza vaccine(SKYCellflu) for influenza infection in South Korea during 2023-2024	17:38 - 17:51	Philip Mudd: Clonally Expanded Tissue-Resident CD8+ T Cells Recognize Conserved Influenza Viral Proteins in the Lower Airways During Acute Human Infection	Shuyi Zhong: Repeated vaccination effects on immunogenicity of influenza vaccine among older adults in Hong Kong	Lea Separovic: Respiratory syncytial virus vaccination among older adults in Canada: number needed to vaccinate and associated costs to prevent severe outcomes
17:39 - 17:52	Danuta Skowronski: XBB.1.5 vaccine effectiveness against medically-attended COVID-19, including JN.1-specific cross-protection: estimates from the community-based Canadian Sentinel Practitioner Surveillance Network	17:51 - 18:04	Sarah Londrigan: Identification of novel host proteins that are associated with macrophage control of influenza A virus replication	David Bauer: First antigenic exposures to SARS-CoV-2 Spike do not indelibly shape SARS-CoV-2 immunity	Evangeline Obodai: Proof-of-principle of a technology transfer of an RSV neutralization assay to a GAVI eligible country
17:52 - 18:05	Hannah C Moore: Integrating community attitudes with population-based epidemiological data for RSV immunisation policy: the STAMP program	18:04 - 18:17	Benjamin Lindsey: Mucosal and blood transcriptome differentiates diverse immune trajectories following vaccination with live attenuated influenza vaccine in children	Esther Kissling: Vaccine effectiveness against influenza A(H1N1)pdm09 and A(H3N2) and birth cohort effect: Results from the 2023–24 season European VEBIS primary care multicentre study	Antoine Brault: Estimates of effectiveness and impact of nirsevimab on hospitalisations for RSV bronchiolitis in France, 2023-2024 : a modelling study
18:05 - 18:30	Panel discussion	18:17 - 18:30	Jiawei Yu: Time-resolved scRNA-seq reveals transcription dynamics of polarized macrophages with influenza A virus infection and antigen presentation to T cells	Isaac Cheuk Long Chow: Impact of Influenza A(H3N2) virus infection on the antibody landscapes of hemagglutinin and neuraminidase protein in older adults.	Christopher Blyth: Evaluating the Nirsevimab RSV prevention program in Western Australia - early insights into program impact
18:30 - 20:30	Poster Session 2				

Time	DAY 3: TUESDAY 1 OCTOBER 2024				
07:00 - 12:00	<i>Registrations and Poster Set Up</i>				
08:00 - 10:00	Great Hall 1 and 2				
	Immunology and Vaccine Development				
08:00 - 08:10	Opening - Conference Business and Session welcome Chairs: Katherine Kedzierska and Chris Chiu				
08:10 - 08:45	Stephanie Langel , Case Western Reserve University, USA Influenza and the Mammary Gland: Vaccine Strategies That Boost Breast Milk Anti-Influenza Immunity				
08:45 - 09:20	Stephanie Gras , La Trobe University, Australia The good, the bad and the ugly: the role of HLA in COVID-19				
09:20 - 09:55	Ali Ellebedy , Washington University School of Medicine, St Louis, USA B cell responses to mRNA vaccination: Lesson from the pandemic				
10:00 -10:30	Morning Tea				
10:30 - 11:30	Industry Symposium: Moderna Addressing Influenza Disease Burden: Current Challenges and Emerging Vaccine Strategies Against a Persistent Threat Chair: Michael Nissen Raina MacIntyre , Colin Russell , Terry Nolan AO (Great Hall 1 and 2)				
11:30 - 13:00	Great Hall 1 and 2	Mezzanine Room M4	Mezzanine Room M3		Mezzanine Room M1 and M2
	Public Health and Policy	Other Respiratory Viruses	11:30 - 13:00	Interdisciplinary Session	Clinical Sciences and Vaccinology
	Vaccines 3: immunogenicity, efficacy and effectiveness <i>Chairs: Sascha Ellington and Stephany Sanchez-Ovando</i>	SARS-CoV-2 and other virus transmission and evolution <i>Chairs: Larisa Labzin and Benjamin Meyer</i>		Correlates of protection and immune responses to vaccination <i>Chairs: Ann Falsey and Nancy Leung</i>	AVG IG Session <i>Chairs: Kimberly Armstrong and Michael Ison</i>
11:30 - 11:43	Sascha Ellington: Influence of Birth Cohort on 2023-2024 Influenza Vaccine Effectiveness Against A(H1N1)pdm09-Associated Illness in the United States	Carlos Grijalva: Role of immunity in the transmission of SARS-CoV-2 infections in households: evidence from case-ascertained studies	11:30 - 11:55	Chris Chiu: Immune correlates of symptomatic and asymptomatic disease following controlled human influenza virus infection	Cameron Wolfe:
11:43 - 11:56	Ausenda Machado: COVID-19 vaccine effectiveness in the paediatric population aged 5–17 years: a multicentre cohort study using electronic health records in six European countries	Osiean Teng: Biomarkers of early SARS-CoV-2 infection prior to the onset of respiratory symptom	11:55 - 12:07	Brendan Flannery: Application of test-negative design for serologic correlates of protection against laboratory-confirmed influenza and COVID-19	Ultan Power: Identification and Validation of Azatadine-Dimaleate as a Potent Antiviral against SARS-CoV-2: Potential for Clinical Development Alone or in Combination with Remdesivir
11:56 - 12:09	Stephany Sanchez-Ovando: Influenza vaccine A(H1N1)pdm09 strain change effects on immunogenicity among repeatedly vaccinate healthcare workers	Simon Cauchemez: A new modelling framework to decipher the contribution of RNA viral loads dynamics on household transmission of SARS-CoV-2	12:07 - 12:20	Yang Wang: Population susceptibility prior to Omicron emergence, and antibody correlates of protection against first and second omicron waves: findings from the HIVE study	Yuko Tsuge: Analysis of the ensitrelvir treatment-emergent amino acid substitutions observed in the SCORPIO-SR phase 3 trial
12:09 - 12:22	Angie Rose: Vaccine effectiveness against influenza A in older adults and the impact of chronic conditions: Results from the I-MOVE and VEBIS European hospital networks, 2015/16–2023/24	Benjamin Meyer: Mucosal Immunity: the key to reduce SARS-CoV-2 transmission?	12:20 - 12:33	Tim Russell: Real-time estimation of immunological responses against emerging SARS-CoV-2 variants	Nadine Sicard: Implementation evaluation of the nirmatrelvir/ritonavir (Paxlovid TM) rollout in Canada during the COVID-19 response: lessons learned for pandemic preparedness
12:22 - 12:35	Ben Cowling: Repeated influenza vaccination effects in a randomized placebo-controlled trial (the DRIVE study)	Sadegh Niazi: Unveiling Airborne Risks: Assessing Respiratory Virus Transmission Through Cough Particles	12:33 - 12:46	Sophie Valkenburg: Adjuvant advantage in a longitudinal randomized control trial of alternating enhanced influenza vaccines in older adults	Ryuta Uraki: Drug Susceptibility and the Potential for Drug-Resistant SARS-CoV-2 Emergence in Immunocompromised Animals
12:35 - 12:48	Emily Rayens: Comparative effectiveness of cell-based vs. egg-based influenza vaccines in prevention of influenza hospitalization during the 2022-2023 season among adults 18-64 years	Harm van Bakel: The role of persistent infections in SARS-CoV-2 evolution	12:46 - 12:59	Boitumelo Motsoeneng: Hemagglutinin stalk-specific Fc-mediated functions are associated with protection against influenza-illness after seasonal influenza vaccination in pregnant women	Mirella Salvatore: Emergence of antiviral resistance in the immunocompromised host with SARS-CoV2 infection
12:48 - 13:01	Alicia Stein: Relative vaccine effectiveness of cell-based versus egg-based quadrivalent influenza vaccines against test-confirmed influenza in the United States 2022-23 influenza season	Amaya Rojo Fernandez: CIDS: A household cohort study of COVID-19			
13:00 - 14:00	Lunch				
14:00 - 15:00	Industry Symposium: Sanofi OLD disease, NEW ways to better assess vaccine performance Chair: LJ Tan Bruno Lina , Raina McIntyre , Tor Biering-Sorensen (Great Hall 1 and 2)				
	Great Hall 1 and 2	Mezzanine Room M3	Mezzanine Room M4	Mezzanine Room M1 and M2	
15:00 - 16:30	Public Health and Policy	Virology and Pathogenesis	Other Respiratory Viruses	Clinical Sciences and Vaccinology	
	Sero-epidemiology <i>Chairs: Aubree Gordon and Bingyi Yang</i>	Adaptive immune response to infection <i>Chairs: Annette Fox and Thi Hoang Oanh Nguyen</i>	Pathogenesis <i>Chairs: Julie McAuley and Anika Singanayagam</i>	Antivirals and therapeutics <i>Chairs: Elena Govorkova and Jude Jayamaha</i>	

15:00 - 15:25	Sheena Sullivan: Methodological considerations in sero-epidemiology studies	Paul Thomas: Defining specific cellular correlates of protection against influenza	Stanley Perlman: Long term sequelae in SARS-CoV-2-infected mice and humans	Emi Takashita: Antiviral susceptibilities of influenza virus and SARS-CoV-2	
15:25 - 15:38	Zhunan Li: Serologic evidence of co-circulation of three respiratory viruses from a longitudinal population immunity study in the United States	Ian Wilson: Diverse binding modes of VH1-69 encoded antibodies to the influenza virus HA stem	Louise Rowntree: Long COVID patients establish and maintain SARS-CoV-2-specific CD8+ T cells with effector phenotype	James Antoon: Oseltamivir Use and Risk of Serious Neuropsychiatric Events in Children and Adolescents	
15:38 - 15:51	Serena Marchi: Prevalence of influenza B/Yamagata viruses from season 2012/2013 to 2021/2022 in Italy as an indication of a potential lineage extinction	Caroline Page: Differential immune responses elicited from contemporary influenza B infection allow for asymmetric cross-protection between the lineages	Anika Singanayagam: Development and early results from a SARS-CoV-2 Delta variant human infection challenge model	Fahmida Chowdhury: Antimicrobial Use Patterns among Patients with Influenza-associated Severe Acute Respiratory Infections at Tertiary-care Hospitals in Bangladesh (2010–2023)	
15:51 - 16:04	Nokuthula Linda: Influenza sero-protection during the COVID-19 pandemic: HUTS Community Cohort Study, South Africa, 2021	Thi Hoang Oanh Nguyen: Recovery from severe and fatal influenza virus infection relies on effective adaptive immunity: post-COVID-19 pandemic experience	Helen Mostafavi: Mechanisms driving endothelial dysfunction in acute COVID-19	Taylor Sandison: Safety Data from Phase 1 and Phase 2a Studies of CD388, a Drug Fc-conjugate for Seasonal Pan-Influenza Prophylaxis	
16:04 - 16:17	Weijia Xiong: Using antibody titers as a measure of influenza population immunity: insights from a longitudinal serology study in Hong Kong, 2009-2014	Kristin G-I Mohn: Immune kinetics in hospitalized patients following moderate and severe influenza infection.	Jane Sinclair: Cardiovascular symptoms of PASC are associated with trace-level circulatory cytokines that affect the function of primary human cardiomyocytes	Jeremy C. Jones: Baloxavir antiviral intervention protects ferrets from severe influenza A(H5N1) clade 2.3.4.4b viral disease and neuroinvasion	
16:17 - 16:30	Raquel Guimar: Higher susceptibility in younger adults born from 1970 to 1976 for influenza A(H1N1) infection: results from a repeated seroprevalence survey 2016 to 2023	Wuji Zhang: Interferon pathways are enhanced in influenza-specific B cells following influenza virus infection compared to vaccination	Julie McAuley: Identifying the neurological impact of COVID-19 in a mouse of model of SARS-CoV-2 infection	Larisa Gubareva: Monitoring susceptibility of influenza viruses to baloxavir: update on testing algorithm and findings	
16:30 - 17:00	Afternoon Tea <i>*All posters in Exhibition Hall 1 to be removed</i>				
17:00 - 18:30	Great Hall 1 and 2 Public Health and Policy Epidemiology, transmission, and control <i>Chairs: Emily Ricotta and Marc-Alain Widdowson</i>	Mezzanine Room M3 Interdisciplinary Session Epidemic and pandemic preparedness <i>Chairs: Florian Krammer and Christine Oshansky</i>	Mezzanine Room M4 Other Respiratory Viruses SARS-CoV-2 novel treatments and prevention strategies <i>Chairs: Kanta Subbarao and Rubina Bunjun</i>	Mezzanine Room M1 and M2 Clinical Sciences and Vaccinology Diagnostics, biomarkers and applications <i>Chairs: Ryan Thwaites and Maria Zambon</i>	
17:00 - 17:25	Emily Ricotta: Why improving observational studies is critical for ensuring high-quality infectious disease policy	Jodie McVernon: Modelling to support equitable benefits from vaccines and countermeasures against 'Disease X'	Kanta Subbarao: A comparison of antibody responses following homologous and heterologous COVID-19 vaccines and breakthrough infections in previously naive and convalescent individuals	Ryan Thwaites: Early mucosal responses to respiratory viruses in natural infections and human challenge studies	
17:25 - 17:38	Sue Huang: Impact of COVID-19 and influenza on SHIVERS longitudinal community and household cohorts in New Zealand	Marciela Degrace: Protection from Pandemic Influenza on Day 1: BARDA's Vision for Influenza Vaccine Development	Stephan Ludwig: Clinical Proof of Concept for a Novel Host-Targeted Anti-Infective Strategy Against COVID-19 and Other Acute Respiratory Viral Diseases	Jeremy Chase Crawford: OLAH and its main catalytic products act as early biomarkers of life-threatening illness from diverse viral respiratory infections	
17:38 - 17:51	Sarah Cox: Years: Influenza Incidence among Children and Adults 6 Months to 49 Years: The Cascadia Prospective Cohort Study, United States, 2022-2023	Magdi Samaan: Pandemic Risk Assessment of Avian Influenza A(H5N1) Clade 2.3.4.4b Viruses Using the WHO TIPRA	Teresa Aydllo: Concomitant administration of seasonal influenza and COVID-19 mRNA vaccines	Benjamin Larsen: Using occluded Cas13 to detect influenza mutations at the point of care	
17:51 - 18:04	Nancy Hiu Lan Leung: Multiple introductions and co-transmission of respiratory viruses in same households (TReV study)	Honglei Sun: Potential epidemic or even pandemic of H3N2 avian influenza A virus: public health concern and preparedness	Rubina Bunjun: Cross-reactive antibody responses to SARS-CoV-2 in South Africa	Luca Ferretti: Digital contact tracing: insights from a new tool to reduce and understand the transmission of respiratory pathogens	
18:04 - 18:17	Jonathan Temte: Factors associated with transmission across three waves of SARS-CoV-2 in a prospective community-based study of households with school-aged children – Dane County, Wisconsin, 2020-2022	Wan Ting Teo: A conceptual approach for pandemic preparedness planning against Disease X	Sam Afkhami: A next-generation inhaled aerosol COVID-19 vaccine fills the gap in respiratory mucosal immunity in humans	Jurre Siegers: Evolutionary Dynamics and Zoonotic Potential of H6, H10, and H11 Avian Influenza Viruses: A Comprehensive Study from Cambodia, 2019-2022	
18:17 - 18:30	Cayla Reddy: Influenza antibody titres before and during the COVID-19 pandemic: A community cohort study in South Africa (PHIRST, PHIRST-C)	Alvin X. Han: A novel mathematical framework to inform global antiviral stockpile size and distribution for influenza pandemic mitigation	David Hodgson: Memory B cell proliferation drives differences in neutralising responses between ChAdOx1 and BNT162b2 vaccines	Georgina McCallum: The Host Response as a Novel Diagnostic Biomarker for 'Pre-positive' viral infection	
60 minute gap between Congress and Social					
19:30 - 23:00	OPTIONS XII Congress Party @ Eat Street Northshore				

Time	DAY 4: 2 OCTOBER 2024				
07:00 - 08:00	Registrations				
	Great Hall 1 and 2				
08:00 - 10:00	Zoonotic Infection / Emerging Viruses				
08:00 - 08:10	Opening - Congress Business and Session welcome Chairs: Stacey Schultz-Cherry and Michelle Wille				
08:10 - 08:45	Malik Peiris, University of Hong Kong, Hong Kong MERS coronavirus remains a pandemic threat?				
08:45 - 09:20	Marianna Leguia, Pontificia Universidad Catolica del Peru, Peru Highly Pathogenic Avian Influenza A (H5N1) in Marine Mammals and Seabirds in Peru				
09:20 - 09:55	Andrew Bowman, The Ohio State University, USA Bovine influenza: Holy cow!				
10:00 - 10:30	Morning Tea				
10:30 - 11:30	This Week In Virology (Great Hall 1 and 2)				
	Great Hall 1 and 2	Mezzanine Room M3	Mezzanine Room M4	Mezzanine Room M1 and M2	
11:30 - 13:00	Public Health and Policy Burden of disease <i>Chairs: Danielle Iuliano and Jessica Y. Wong</i>	Virology and Pathogenesis Pathogenesis and transmission <i>Chairs: Ian Wilson and Philipp Peter Petric</i>	Other Respiratory Viruses SARS-CoV-2 vaccines <i>Chairs: Carissa Aurelia and Stanley Perlman</i>	11:30 - 13:00	Interdisciplinary Session Late Breaking Abstracts on H5N1 in new species <i>Chairs: Andrew Bowman and Agustina Rimondi</i>
11:30 - 11:55	Danielle Iuliano: Modernizing influenza burden estimation and the necessity of rethinking assumptions	Stacey Schultz-Cherry: Influenza in indigenous communities	Michael Chan: Experimental platform of human respiratory tract for risk assessment of emerging respiratory virus infection	11:30 - 11:43	Amy Baker: Experimental reproduction of viral replication and disease in dairy calves and lactating cows inoculated with highly pathogenic avian influenza H5N1 clade 2.3.4.4b
11:55 - 12:08	Jessie Goldsmith: Using data from the COVID period to improve our understanding of the burden of influenza mortality	Charlotte Kristensen: Mind-Boggling: Influenza A Virus Presence in the Brain of Inoculated Pigs and Ferrets	Deborah Cromer: Predicting COVID-19 booster immunogenicity against future SARS-CoV-2 variants and the benefits of vaccine updates	11:43 - 11:56	Jenna Guthmiller: A single mutation in dairy cow-associated H5N1 viruses increases receptor binding breadth
12:08 - 12:21	Anand Krishnan: Influenza among older adults in India: Disease burden and cost-effectiveness of introduction of a vaccination program	Lisa Kercher: The use of telemetry and whole-body plethysmography for acquiring real-time physiological data for improved host response analysis during an influenza virus infection in ferrets.	Vivek Shinde: Safety and Immunogenicity of an investigational influenza protein vaccine and COVID and influenza combination protein vaccine	11:56 - 12:09	Douglas Reed: Inhalation of aerosolized A/Chile/25945/2023 (clade 2.3.4.4b H5N1) virus triggers fever, severe respiratory disease, and a lethal outcome in cynomolgus macaques
12:21 - 12:34	Janine Paynter: Population-based SARI-influenza in 2022 vs pre-pandemic baseline in Auckland, New Zealand	Mark Zanin: S213P in the non-structural protein 1 of subtype H1N1 avian influenza A viruses mediates airborne transmissibility in the ferret model.	Yang Wang: A 10-valent composite mRNA vaccine against both influenza and COVID-19	12:09 - 12:22	Patrick Reading: Bovine Myxovirus resistance protein 1 mediates antiviral activity against against human and avian influenza A viruses
12:34 - 12:47	Jessica Y. Wong: Influenza-associated excess mortality associated with influenza B in Hong Kong, 2014-2019	Stacey Bartlett: The role of nasal inflammation in the transmission of influenza A virus in an infant mouse model	Kevin Selva: Boosting four-mula: Characterizing elevated IgG4 following repeated COVID-19 mRNA boosters.	12:22 - 12:35	Justin Shepard: Bovine A(H5N1) Influenza Virus Receptor Binding Specificity
12:47 - 13:00	Nicole Wolter: Attributable fraction of influenza and respiratory syncytial virus in infants aged <1 year hospitalized with respiratory and non-respiratory illness in South Africa, 2016-2018	Michelle Vu: Impact of multiple donors on transmission efficiencies in the ferret playpen model	Carissa Aurelia: Functional consequence of increased IgG4 levels upon repeated SARS-CoV-2 mRNA vaccination.	12:35 - 12:48	Jonathan Heeney: A Computationally Designed pan-H5Nx Vaccine Induces Broad Subtype Neutralising Antibody Responses Compared to Whole Inactivated H5 Vaccines
				12:48 - 13:00	Charlotte Kristensen: In Situ Expression of Influenza A Virus Receptors in the Bovine Mammary Gland Elucidated by Lectin Histochemistry
13:00 - 14:00	Lunch				
	Great Hall 1 and 2	Mezzanine Room M3	Mezzanine Room M4	Mezzanine Room M1 and M2	
14:00 - 15:30	Public Health and Policy Surveillance <i>Chairs: Erik Karlsson and Wilhelmina Strasheim</i>	Virology and Pathogenesis Zoonotic respiratory viruses: mechanisms of zoonoses <i>Chairs: Juan Pu and Malik Peiris</i>	Interdisciplinary Session Past pandemics and future solutions <i>Chairs: Georgina McCallum and Patrick Reading</i>	Clinical Sciences and Vaccinology Novel vaccines and platforms Sponsored by Vaxxas <i>Chairs: Arne Matthys and Shane Crotty</i>	
14:00 - 14:25	Nicole Wolter: Adapting sentinel surveillance to address priority diseases in South Africa	Massimo Palmarini: Human genetic barriers to spillover of avian influenza viruses	Svenn-Erik Mamelund: Old data gives new clues to the "mother" of all pandemics	Paul Young: The Molecular Clamp Platform: A broadly applicable solution to the manufacture of subunit vaccines for respiratory viruses	
14:25 - 14:38	Félix Alberto Gundane Albati: Establishment of epidemic parameters and thresholds for assessing the severity of Pandemic Influenza in Mozambique between 2015 and 2024.	Nico Joel Haiwe: The bat-derived H9N2 Influenza A virus displays pre-pandemic traits despite a limited host range	Mark-Alain Widdowson: WHO's Unity Studies: a standardised preparedness framework critical for the investigation and study of novel or re-emerging respiratory pathogens for an effective and proportionate response	Irina Isakova-Sivak: Development of a modified trivalent live attenuated influenza vaccine for combined protection against seasonal influenza and COVID-19	
14:38 - 14:51	Wenqing Zhang: Epidemic patterns of respiratory syncytial virus in select countries participating in the WHO pilot surveillance project, 2017–23	Juan Pu: An emerging PB2-627 polymorphism increases the pandemic potential of avian influenza virus by breaking through ANP32 host restriction in mammalian and avian hosts	Lauren Steele: Unlocking Spatially resolved Transcriptomic and Proteomic Secrets of Century-Old Lungs from the 1918 'Spanish' Influenza Pandemic	Tomer Hertz: The M2SR intranasal H3N2 single-replication live influenza vaccine induces more potent and broad mucosal sIgA response in older adults than the high-dose inactivated FluzoneHD vaccine	

14:51 - 15:04	Eva Kozanli: Co-infection and co-circulation dynamics of SARS-CoV-2 in the Dutch respiratory season of 2022/2023	Stephanie Williams: Avian influenza A virus polymerase gene leads to temperature-resistant viral RNA genome replication	Matthew Miller: Next Generation Approaches for Broadly Protective Mucosal Vaccines	Angus Forster: Lower doses of quadrivalent seasonal influenza vaccine generate significantly improved antibody titres delivered with a simple to apply skin patch (phase 1 study)	
15:04 - 15:17	Camille Esneau: The PREVENT Study – An Assessment of Virus Circulation in the Hunter New England Community	Mark Anthony Casel: Amino acid changes in HA in HPAI H5N1 viruses alter receptor binding affinity and enhance virulence in mammalian hosts	David Muller: Understanding the enhanced immune responses to High-Density Microarray Patch vaccination through spatial transcriptomics and antibody repertoire analysis	Sean Ray: A minimalist, self-adjuvanting vaccine achieves robust immune response to conserved influenza peptide M2e	
15:17 - 15:30	Ariful Islam: Integration of SARS-CoV-2 testing into influenza sentinel surveillance for pandemic preparedness: Findings from Hospital-based Influenza Surveillance in Bangladesh, 2020-2023	Francesco Bonfante: Genetically diverse European H3Nx avian influenza viruses rapidly select pre-pandemic adaptive mutations at the level of the hemagglutinin gene upon one passage in ferrets	Yiyang Guo: Optimizing Situational Awareness During the COVID-19 Pandemic: A Syndromic Surveillance Approach for Early Detection of Symptom Combinations	Juan Manuel Carreño Quiroz: Development of a multivalent nucleoside-modified mRNA vaccine that broadly protects against influenza A and B viruses	
15:30 - 16:00	Afternoon Tea <i>*All posters in Great Hall to be removed</i>				
Great Hall 1 and 2					
16:00 - 17:30 Closing Ceremony Chairs: Kirsty Short and Mark Tompkins					
16:00 - 16:35 Maria van Kerkhove , World Health Organization, Switzerland					
16:35 - 17:10 Steven Riley , Imperial College, United Kingdom Public health dynamics for respiratory viruses: pandemic times and afterwards					
17:10 - 17:20 Awards					
17:20 - 17:30 Closing remarks and thanks					